Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OZOBAX DS vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Treatment of spasticity associated with multiple sclerosis,Treatment of spinal cord injury-induced spasticity
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
250-350 mg orally 3 times daily and at bedtime
Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (Cr Cl 30-50 m L/min) and up to 20-30 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Hepatic metabolism via deamination; minor CYP450 involvement.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5%
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
20-30% bound to serum albumin.
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
0.2-0.3 L/kg; indicates distribution primarily into extracellular fluid.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral: 95-100% (well absorbed); intravenous: 100%.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
e GFR 30–59 m L/min/1.73 m²: 300 mg twice daily. e GFR 15–29 m L/min/1.73 m²: 200 mg twice daily. e GFR <15 m L/min/1.73 m²: 200 mg once daily.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: 400 mg per day in divided doses. Child-Pugh Class C: not recommended.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Children (6–12 years): 10–15 mg/kg per dose twice daily, max 600 mg daily. Adolescents (12–18 years): same as adult dosing.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Start at the lower end of the dosing range (600 mg/day in divided doses) and titrate based on renal function; monitor for side effects.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
Abrupt discontinuation may precipitate withdrawal syndrome, including severe hyperthermia, altered mental status, and muscle rigidity, which can be life-threatening. Taper slowly.
None
Risk of withdrawal syndrome with abrupt cessation,Dose-dependent sedation and dizziness may impair ability to drive or operate machinery,May exacerbate psychiatric disorders; use with caution in patients with depression or schizophrenia,Renal impairment requires dose adjustment,Respiratory depression risk, especially with concomitant CNS depressants
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Hypersensitivity to baclofen or any component of the formulation,Concurrent use of tricyclic antidepressants may increase risk of respiratory depression
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
No specific food interactions; however, taking with food may reduce gastrointestinal discomfort.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
Ozobax DS (baclofen) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, baclofen has been shown to increase the incidence of omphalocele (ventral hernia) in fetuses of rats given approximately 3 times the maximum human dose. In rabbits, an increased incidence of incomplete ossification of sternal centers was observed. Cases of neonatal withdrawal syndrome have been reported with chronic maternal use during the third trimester, presenting as hypertonia, tremor, and seizures. Therefore, use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Avoid use in the first trimester unless clearly needed.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Baclofen is excreted into human breast milk in low concentrations. The milk-to-plasma (M/P) ratio is approximately 0.4. The estimated infant dose from breast milk is about 0.1 mg/kg/day, which is less than 1% of the maternal weight-adjusted dose. No adverse effects in nursing infants have been reported. However, caution is advised, especially in premature infants or those with renal impairment. Monitor the infant for sedation, hypotonia, or feeding difficulties.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
During pregnancy, increased plasma volume and enhanced renal clearance may reduce baclofen plasma concentrations, potentially requiring dose adjustments. However, specific pharmacokinetic data in pregnancy are limited. Dosing should be individualized based on clinical response. Monitor for deterioration of symptoms (e.g., increased spasticity) and adjust dose accordingly. If dose increased during pregnancy, reduce gradually postpartum to avoid withdrawal in both mother and neonate.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
OZOBAX DS (baclofen) is a GABA-B receptor agonist used for spasticity. Dosage titration is critical to avoid adverse effects. Abrupt discontinuation can cause withdrawal (hallucinations, seizures). Monitor for respiratory depression, especially in elderly or renal impairment. Consider dose adjustment in renal impairment (Cr Cl <30 m L/min).
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Take exactly as prescribed; do not stop suddenly.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol as it may worsen side effects.,Report any signs of withdrawal: confusion, hallucinations, seizures.,Take with food to reduce stomach upset.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OZOBAX DS vs CARISOPRODOL, answered by our medical review team.
OZOBAX DS is a Skeletal Muscle Relaxant that works by Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OZOBAX DS and CARISOPRODOL depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OZOBAX DS is: Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OZOBAX DS and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OZOBAX DS is classified as Category C. Ozobax DS (baclofen) is classified as FDA Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, baclofen has been shown to i. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.